FF-10502 is under clinical development by Fujifilm and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how FF-10502’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

FF-10502 overview

FF-10502 is under development for the treatment of metastatic solid tumors, lymphoma, advanced/recurrent pancreatic and ovarian cancer, cholangiocarcinoma, parotid gland, prostate cancer, sarcoma, endometrial cancer, squamous cell carcinoma of the head and neck, anal, colon-neuroendocrine cancers. It is a synthetic pyrimidine nucleoside analogue administered through intravenous route. It acts by targeting DNA polymerase. It is based on the Fujifilm's organic synthesis technology.

Fujifilm overview

Fujifilm designs, manufactures, and markets healthcare solutions, material solutions, document solutions and imaging systems. The company offers document solutions such as office products, office printers, and allied production services and global services. Its major products include color films, color paper and chemicals, photofinishing equipment, electronic imaging and optical devices, TV camera lenses, security lenses, healthcare products, graphic systems, flat panel display materials, recording media and industrial products. Fujifilm also offers equipment and materials for medical systems, cell culture media and reagents, pharmaceuticals, cosmetics, and supplements. The company serves individual consumers and business enterprises. The company has business presence in the Americas, Europe, and Asia-Pacific. Fujifilm is headquartered in Minato-Ku, Tokyo, Japan.

For a complete picture of FF-10502’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.